4CPS-166 Switching to alemtuzumab in patients with relapsing remitting multiple sclerosis

BACKGROUND: Alemtuzumab is a monoclonal antibody directed against the CD52 antigen on T- and B-lymphocytes indicated in adult patients with relapsing remitting multiple sclerosis (RRMS). PURPOSE: To assess safety, reason for switching, compliance with the protocol and with the criteria for use. MATE...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Eur J Hosp Pharm
Glavni autori: Arias, A, Blanc, R Menárguez, Torrón, A Martínez, Fernández, C Carriles, María, MC Rosado, Roces, L Velasco, García, I Zapico, Lozano-Blázquez, A
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2018
Teme:
Section 4: Clinical pharmacy services
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535247/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.257
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items